Treatment for restless legs syndrome (RLS) is chosen from the pattern and burden of symptoms, iron results, aggravating factors, pregnancy, other health conditions, and previous treatment. There is no single best medicine for everyone. Current guidance starts by confirming that the symptoms really fit RLS, checking iron status, and correcting modifiable contributors before selecting a long-term therapy 12.
This guide focuses on treatment decisions after RLS has been diagnosed or is strongly suspected. If you are still trying to identify the symptom pattern, start with the RLS overview or the guide to diagnosing restless legs syndrome.
What determines the treatment plan?
A clinician first needs to know whether symptoms are occasional, frequent enough to disrupt sleep or quiet activities, or difficult to control despite treatment. The plan also changes when symptoms began or worsened during pregnancy, when kidney disease or neuropathy is present, or when a person has already used a dopamine medicine.
| Situation | Main treatment question |
|---|---|
| Occasional, mild symptoms | Can aggravating factors and low-risk relief measures make treatment unnecessary? |
| Clinically significant symptoms | Do ferritin and transferrin saturation support oral or intravenous iron treatment? |
| Chronic persistent symptoms in an adult | Is an alpha-2-delta medicine appropriate after considering sleepiness, breathing, fall, kidney, and misuse risks? |
| Symptoms on a dopamine medicine | Is this undertreatment, rebound, or medication-induced augmentation? |
| Severe symptoms despite appropriate treatment | Does the diagnosis need review, or is specialist treatment such as supervised combination therapy, an opioid, or peroneal nerve stimulation warranted? |
| Pregnancy, childhood, or end-stage kidney disease | Which population-specific treatments and monitoring rules apply? |
The diagnosis should be reconsidered if the main complaint is a fixed pain, cramp, numbness, swelling, weakness, or restlessness that does not improve with movement or become worse at night. Neuropathy, medication-related akathisia, nocturnal cramps, and joint or positional discomfort can resemble parts of RLS but require different care 1.
Start with iron and aggravating factors
Ask for a full RLS iron assessment
The 2025 American Academy of Sleep Medicine (AASM) guideline advises regular iron studies for clinically significant RLS. These should include ferritin and transferrin saturation, calculated from serum iron and total iron-binding capacity. The guideline prefers a morning sample after avoiding iron-containing foods and supplements for at least 24 hours, although you should follow the ordering clinician's instructions 1.
Ferritin estimates stored iron, but it can rise during inflammation and look reassuring when available iron is still low. Transferrin saturation adds information about how much circulating iron is available. A normal blood count or a ferritin result inside a laboratory's general reference range does not by itself answer the RLS treatment question 31.
RLS guidelines use treatment thresholds that differ from ordinary anemia thresholds, and the current frameworks are not identical:
- The 2025 AASM good-practice statement cites consensus thresholds that have not been empirically tested. It says clinicians may consider oral or intravenous iron in adults when ferritin is at or below 75 ng/mL or transferrin saturation is below 20%. If ferritin is between 75 and 100 ng/mL, it directs treatment to intravenous rather than oral iron 1.
- The 2026 RLS Foundation algorithm broadens intravenous iron consideration for selected adults with chronic persistent RLS. It includes people with transferrin saturation below 45% and ferritin from 75 to 300 ng/mL. At lower ferritin levels, it also considers intravenous iron when oral iron cannot be absorbed or tolerated, has not worked after a monitored trial, or is unlikely to meet the needs of someone with severe symptoms 2.
These numbers guide a clinician who has the full history and laboratory context. They are not proof that iron is the cause of every case, a target to chase with supplements, or permission to start iron without checking for blood loss, absorption problems, inflammation, kidney disease, pregnancy, or iron overload risk.
Oral and intravenous iron are not interchangeable
Oral ferrous sulfate has a conditional AASM recommendation for adults with appropriate iron status. It is accessible, but absorption becomes limited as ferritin rises and constipation or other digestive effects can make it difficult to continue. Intravenous ferric carboxymaltose has a strong AASM recommendation for appropriate adults, supported by randomized trials. Other intravenous formulations have different evidence, administration requirements, and adverse-effect profiles 1.
A 2025 meta-analysis of 12 randomized trials found that iron treatment improved RLS severity, quality of life, and a sleep rating compared with placebo, with the clearest evidence for ferric carboxymaltose. The trials varied in formulation, iron status, and population, so the pooled result does not show that every person with RLS should receive iron or that every product works the same way 4.
Intravenous iron requires supervised administration and formulation-specific monitoring. Ferric carboxymaltose can lower phosphate levels, while oral iron can cause constipation, nausea, abdominal discomfort, vomiting, or diarrhea 13. Too much iron can cause serious harm, and accidental overdose is especially dangerous for children. Keep iron locked away and use only the product and monitoring plan chosen by the treating clinician 3.
Review medicines, substances, and sleep apnea
The AASM lists alcohol, caffeine, antihistaminergic medicines, serotonergic medicines, antidopaminergic medicines, and untreated obstructive sleep apnea as factors to address early 1. Relevant medicines can include sedating antihistamines in nighttime or allergy products, some antidepressants, antipsychotics, and dopamine-blocking anti-nausea medicines.
This is a medication review, not an instruction to stop needed treatment. Abruptly changing an antidepressant, antipsychotic, anti-nausea medicine, or sedative can create other problems. Bring prescription drugs, over-the-counter products, supplements, nicotine, alcohol, and other substances to the prescriber or pharmacist for review. A change in timing, dose, or product may be reasonable, but only after considering why it was prescribed.
Caffeine and alcohol are not universal causes. If either seems linked to symptoms, a measured reduction and symptom log is more informative than a permanent ban based only on the diagnosis. Snoring, witnessed breathing pauses, gasping, or marked daytime sleepiness should prompt an assessment for sleep apnea rather than assuming RLS explains all disrupted sleep.
Medicines for adults with persistent RLS
Alpha-2-delta medicines
The AASM strongly recommends gabapentin enacarbil, gabapentin, and pregabalin for adults with RLS. The 2026 RLS Foundation algorithm likewise places gabapentinoids first among medicines for chronic persistent RLS 12.
These medicines can reduce symptom severity, but they are not automatically right for every adult. Dizziness and sleepiness are common decision factors. Other sedating medicines, breathing disorders, and a history that raises concern about misuse also affect selection 1.
The U.S. Food and Drug Administration warns that gabapentin and pregabalin can cause serious breathing problems in people with respiratory risk factors. Risk is higher with opioids or other central nervous system depressants, impaired lung function, and older age 5. Tell the prescriber about alcohol and every sedating medicine. Do not drive or do hazardous work if a new treatment makes you sleepy, dizzy, or unsteady.
Why dopamine agonists are no longer routine treatment
Pramipexole, ropinirole, rotigotine, and levodopa can reduce RLS symptoms in the short term. The AASM now suggests against their standard use because long-term dopaminergic treatment can cause augmentation, a treatment-induced worsening that may become more difficult to manage than the original pattern 1.
Possible signs of augmentation include:
- symptoms beginning progressively earlier in the day;
- symptoms starting sooner after sitting or lying down;
- stronger or longer symptoms despite treatment;
- spread to the arms or another previously unaffected area; or
- repeated pressure to take the medicine earlier or raise the dose.
Dopamine agonists can also cause sleepiness, dizziness, and impulse-control problems. New or difficult-to-control compulsive behavior should be reported promptly 1.
A dopamine medicine can still be reasonable for a carefully selected person who values short-term relief, cannot use preferred options, or needs treatment for an occasional period of unavoidable immobility. That choice requires the lowest appropriate exposure and regular monitoring for augmentation and impulse-control changes 1.
Do not respond to possible augmentation by increasing the dose on your own. Do not abruptly stop a dopamine medicine either. Sudden discontinuation can cause dramatic rebound symptoms. Current guidance generally uses a clinician-directed plan that introduces an alternative when needed and tapers the dopamine medicine while monitoring RLS and mood 1.
Rebound is not the same as augmentation
Rebound is the return or worsening of symptoms as a dose wears off or after it is reduced. Augmentation is a progressive shift in the disorder's pattern, especially symptoms starting earlier, appearing faster at rest, intensifying, or spreading 2.
A treatment that seems to have stopped working can also reflect low iron, a new aggravating medicine, sleep loss, untreated sleep apnea, pregnancy, kidney disease, inconsistent dosing, or an incorrect original diagnosis. Record when symptoms begin, where they occur, when each dose is taken, and what movement does. That timeline helps the prescriber distinguish among these possibilities.
Opioids are a selected treatment, not a routine next step
The AASM conditionally supports extended-release oxycodone and, by class extension, other opioids for moderate to severe RLS that remains refractory. Low-dose opioids may also help a specialist manage severe dopamine-related augmentation and taper the dopamine medicine. Most of the randomized evidence comes from one extended-release oxycodone trial, so the evidence is not equally strong for every opioid 1.
This option requires screening, a clear monitoring plan, and attention to sedation, constipation, physical dependence, misuse, overdose, central sleep apnea, and respiratory depression. Combining an opioid with alcohol, benzodiazepines, gabapentinoids, sleep medicines, or other sedatives can further suppress breathing 16.
Do not take extra doses or stop a regularly used opioid abruptly. The FDA warns that rapid reduction can cause withdrawal and uncontrolled symptoms in a physically dependent person. Extreme sleepiness, slow or shallow breathing, confusion, blue or gray lips, or inability to wake or respond is an emergency 6.
Other specialist options
The AASM conditionally recommends bilateral high-frequency peroneal nerve stimulation for selected adults, many of whom had refractory RLS in the trials. The device stimulates nerves below the knees and is not interchangeable with a generic massage pad, compression wrap, vibration product, or home TENS unit. Short-term studies found a small improvement in severity, with uncomfortable stimulation and skin irritation among the reported adverse effects 1.
Dipyridamole also has a conditional AASM recommendation, but it rests on one short randomized trial with low-certainty evidence. Because it is an antiplatelet medicine with its own contraindications and interactions, it is a clinician-selected option rather than a supplement-like remedy 1.
The AASM suggests against clonazepam as an RLS treatment because benefit is uncertain and sedation, cognitive impairment, and dependence matter. A sedative may make someone less aware of disrupted sleep without treating the urge-to-move pattern itself 1.
Pregnancy, children, and kidney disease need separate plans
Pregnancy and breastfeeding
Adult RLS medicine rankings cannot be copied directly into pregnancy or lactation. A 2026 clinical review prioritizes nonmedication measures and iron repletion when indicated, reserving medicines for severe, refractory symptoms after maternal and fetal risks have been weighed 7.
Coordinate persistent or severe symptoms with the obstetric and sleep-medicine teams. Do not add iron beyond the prenatal plan or continue a pre-pregnancy RLS medicine without review. The safety balance changes by medicine, trimester, dose, and breastfeeding status.
Children
The 2025 AASM guideline's only recommended pediatric RLS treatment is ferrous sulfate for children with appropriate iron status, and that recommendation is conditional with very low certainty. Its pediatric ferritin threshold is a clinician's treatment guide, not permission to give a child iron 1. A pediatric clinician should confirm the diagnosis, look for mimics such as cramps or growing pains, and monitor any treatment.
Kidney disease, dialysis, neuropathy, and breathing disorders
End-stage kidney disease has separate iron and medication evidence. The AASM conditionally supports gabapentin and, under specific laboratory conditions, intravenous iron sucrose for adults with RLS on dialysis, but dosing and monitoring belong with the renal team 1.
Neuropathy can mimic RLS or coexist with it. Persistent burning, numbness, sensory loss, or weakness warrants a neurological assessment rather than escalating RLS medicine by assumption. Untreated sleep apnea and chronic lung disease raise concern about sedating treatments, especially when gabapentinoids, opioids, benzodiazepines, or alcohol are combined 15.
What self-care can and cannot do
Walking, gentle movement, comfortable stretching, a warm or cool pack, massage, and an engaging activity during unavoidable sitting may give temporary relief. A regular sleep opportunity and avoiding personal triggers can make symptoms easier to manage. The RLS home-remedies guide explains these low-risk options in more detail.
These measures do not correct low iron or replace treatment for clinically significant RLS. Current AASM recommendations do not establish magnesium, vitamin D, soap under the sheets, valerian, or a broad supplement stack as standard RLS treatment 1. Treat a demonstrated nutrient deficiency on its own terms rather than assuming that restless legs proves one is present.
When to contact a clinician
Arrange an evaluation when the RLS pattern repeatedly delays sleep, disrupts quiet activities, or affects daytime function. Contact the prescriber sooner when:
- treated symptoms shift earlier, intensify, or spread;
- a dose seems to wear off sooner or repeated increases feel necessary;
- a new compulsive behavior, fall, confusion, or troublesome swelling appears;
- symptoms change after a medicine is started, stopped, or adjusted;
- pregnancy begins or breastfeeding plans change; or
- symptoms remain severe despite taking treatment as prescribed.
A suddenly painful, swollen, warm, or red leg is not a typical RLS flare and needs prompt assessment for a blood clot. Chest pain, fainting, coughing blood, or sudden shortness of breath with these symptoms needs emergency care 8.
A leg that suddenly becomes severely painful, pale, cold, numb, or weak can signal an abrupt loss of blood flow and is also an emergency 9.
Seek emergency help for extreme medication-related sleepiness, slowed or difficult breathing, blue or gray lips, or inability to wake or respond 56. Do not drive if RLS-related sleep loss or a treatment makes it hard to stay alert 10.
The bottom line
Effective RLS treatment is a sequence, not a search for one universal remedy. Confirm the pattern, check ferritin and transferrin saturation, address aggravating factors, and match treatment to symptom burden and individual risk.
For many adults with chronic persistent RLS, current guidance favors appropriate iron treatment and alpha-2-delta medicines. Dopamine agonists may still have a limited role, but their augmentation and impulse-control risks require active monitoring. Severe refractory symptoms, augmentation, pregnancy, childhood, and end-stage kidney disease need an individualized plan rather than self-directed iron or medication changes.
